BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
BMO Capital downgraded Eli Lilly (NYSE: LLY) from Outperform to Market Perform with a price target of $64.00 (from $91).
Analyst Alex Arfaei commented, "We believe Sola’s failure in EXPEDITION-3 is clearly a meaningfully negative event as it significantly lowers Lilly’s long-term growth prospects. We’ve lowered our Alzheimer’s pipeline forecast from $6Bn by 2024 to ~$2Bn to reflect lower risk adjusted expectations. We now forecast that Lilly can grow revenues by a CAGR of 3% from 2016 to 2020, below guidance of ~5% because of more cautious views for the diabetes franchise. We forecast ~12% EPS growth through 2020, and now value the stock at ~$64/share. Hence, we are downgrading LLY to Market Perform. This note contains our updated model and scenarios excluding Sola."
Shares of Eli Lilly closed at $75.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades NetApp (NTAP) to Underperform
- Credit Suisse Upgrades Juniper Networks (JNPR) to Outperform
- Oppenheimer Assumes Kempharm (KMPH) at Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!